Home > Healthcare > Medical Devices > Diagnostic Devices > Clinical Chemistry Analyzers Market

Clinical Chemistry Analyzers Market Size

Report ID: GMI8435
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Clinical Chemistry Analyzers Market Size

Clinical Chemistry Analyzers Market size was valued at USD 15.2 billion in 2023 and is estimated to grow at a CAGR of 4.1% between 2024 and 2032. Clinical chemistry analyzers are medical devices used in laboratories to perform chemical analysis of various substances present in biological samples such as blood, serum, plasma, urine, and other bodily fluids. These analyzers utilize advanced techniques and technologies to measure a wide range of biochemical parameters, including electrolytes, enzymes, proteins, metabolites, hormones, lipids, and drugs.

To get key market trends

Download Free Sample

The increasing prevalence of chronic disorders and lifestyle diseases has emerged as a significant driver for the market. For instance, according to the World Health Organization (WHO) 2023 report, noncommunicable diseases (NCDs) accounted for the deaths of 41 million individuals each year, making up about 74% of all global fatalities. Therefore, there is a surge in demand for enhanced monitoring and treatment options, innovative medical technologies, and comprehensive programs for managing conditions such as cardiovascular diseases, diabetes, obesity, and related disorders.

Furthermore, growing adoption of point of care testing signifies a shift towards convenient and rapid diagnostic capabilities, increasing geriatric population, increasing demand for laboratory automation within clinical laboratory services which is estimated to reach USD 409.9 billion by 2032 highlights the need for improving efficiency and scalability in diagnostic testing, among other contributing factors propelling the growth of the market.

Clinical Chemistry Analyzers Market Report Attributes
Report Attribute	Details
Base Year:	2023
Clinical Chemistry Analyzers Market Size in 2023:	USD 15.2 Billion
Forecast Period:	2024 to 2032
Forecast Period 2024 to 2032 CAGR:	4.1%
2032 Value Projection:	USD 21.5 Billion
Historical Data for:	2018 – 2023
No. of Pages:	200
Tables, Charts & Figures:	343
Segments covered:	Product, Test Type, Modality, End-use, and Region
Growth Drivers:	Rising geriatric population Increasing prevalence of chronic disorders and lifestyle diseases Growing adoption of point of care testing devices Increasing demand for laboratory automation
Pitfalls & Challenges:	High cost of instruments Requirement for high capital investment

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global clinical chemistry analyzers market was valued at USD 15.2 billion in 2023 and is estimated to record a CAGR of 4.1% between 2024 and 2032, driven by the increasing prevalence of chronic disorders and lifestyle diseases.

The centralized segment accounted for around USD 6.6 billion revenue size in 2023, as it offers numerous advantages in terms of efficiency, cost-effectiveness, space-saving, standardization, quality control, integration, and scalability.

North America clinical chemistry analyzers industry accounted for USD 6.5 billion revenue in 2023, attributed to growing prevalence of chronic disorders such cardiovascular diseases, diabetes, and cancer.

Abbott Laboratories, Danaher Corporation, EKF Diagnostics, F.Hoffmann-La Roche Ltd., Hitachi Ltd., HORIBA Ltd., Ortho Clinical Diagnostics, QuidelOrtho Corporation, Siemens Healthineers AG, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Sysmex Corporation, and Thermo Fisher Scientific Inc.